Top

Notice of Intent to Sole Source Antiviral - Oseltamivir (Tamiflu)

Active

HSHQDC-15-R-00064Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Department of Homeland Security’s Office of Procurement Operations plans to award a sole source, firm-fixed price contract to Genentech USA, Inc. for the antiviral medication Oseltamivir, known commercially as Tamiflu. This procurement is carried out under FAR 6.302-1, recognizing that Genentech is the only responsible source able to meet the agency’s specific requirements. The contract supports the DHS Office of Health Affairs’ Antiviral Stockpile, which is critical for pandemic and avian influenza preparedness. The stockpile aims to maintain an adequate supply of an FDA-approved antiviral that has demonstrated effectiveness against Influenza A, H1N1, and H5N1 strains, ensuring DHS personnel can be protected and the agency's essential functions can continue during a pandemic. Market research confirms that no other contractors possess the necessary approvals from the CDC and FDA or the capacity to produce and deliver this medication in the required quantities and timeframe. The contract will have a 12-month base period with four additional 12-month option periods. This sole source action is not open for competitive proposals, and any responses to the notice are at the respondents' own expense, with no guarantee that submissions will alter the Government’s determination. The administrative point of contact for this acquisition is Michael Horvath.

General Info

Sole source contract to Genentech for Tamiflu, supporting DHS antiviral stockpile, 12-month base term.

Agency

Department Of Homeland Security → Contract Administration Svcs Division

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedApr 8

special-notice

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Homeland Security → Contract Administration Svcs Division

Contacts1 person available

OfficeWASHINGTON, DC, 20528, USA

Organization / AgencyDepartment Of Homeland Security → Contract Administration Svcs Division

Office AddressWASHINGTON, DC, 20528, USA

Contacts

Michael Horvath

contact@example.gov

+1 (555) 000-0000

Full Description

The Department of Homeland Security (DHS), Office of Procurement Operations (OPO), intends to issue a sole source, firm-fixed price contract under the authority of FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." The Government intends to award to Genentech USA, Inc. at 1 DNA Way, South San Francisco, CA 94080 for the antiviral medicine Oseltamivir (trade name Tamiflu). DHS, Office of Health Affairs (OHA), requires this antiviral medicine for the DHS Antiviral Stockpile for pandemic and avian influenza preparedness. The stockpile is needed in order to have a readily available supply of medicine to protect DHS personnel in the event of a pandemic to ensure the continuity of its essential services and overall critical mission. The medicine must be approved by the Food and Drug Administration and demonstrated by the Centers for Disease Control to be effective in treating Influenza A, H1N1 Influenza and H5N1 Avian Influenza. Market research has shown that no other known contractors presently exist who could get the necessary CDC/FDA approvals to produce the product in sufficient quantities and deliver it in time to meet the current requirement. This notice of intent is not a request for competitive proposals. The Government does not anticipate receiving responses to this notice of a non-competitive action. If parties choose to respond, any cost associated with preparation and submission of data or any other cost incurred in response to this announcement are the sole responsibility of the respondent and will not be reimbursed by the Government. The point of contact for this purchase is listed below. A determination by the Government not to open the requirement to competition based upon the responses to this notice is solely within the discretion of the Government. The ordering period of the resulting contract will include a 12-month base and four (4) 12-month options.